Clinical Trials on Advanced or Refractory Solid Malignancies in Korea, Republic of

Total 390 results

Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Revolution Medicines, Inc.
Sanofi

Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Solid Tumor

United States, Korea, Republic of
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

HIV Infection | Advanced Malignant Solid Neoplasm | Kaposi Sarcoma | Lung Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Anal Carcinoma | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States, Australia
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia
BioMed Valley Discoveries, Inc

Terminated

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Advanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene Alteration

United States
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)

Advanced or Metastatic Colorectal Cancer

United States, Korea, Republic of, Taiwan, Malaysia, Germany, Italy, Spain, Belgium, Canada, Puerto Rico, China
Children's Oncology Group
National Cancer Institute (NCI); Pfizer

Completed

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Childhood Anaplastic Large Cell Lymphoma

United States, Canada
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Pfizer

Completed

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)

Systemic Anaplastic Large-Cell Lymphoma | Non-Small Cell Lung Cancer ALK-positive | Non-Small Cell Lung Cancer c-Met Dependent | Non-Small Cell Lung Cancer ROS Marker Positive | Advanced Malignancies Except Leukemia

United States, Korea, Republic of, Australia, Japan
Children's National Research Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Melanoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid Tumor

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Bayer

Terminated

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Relapsed or Refractory Solid Tumors or Lymphoma in Children

United States
Regeneron Pharmaceuticals
Pacific Pediatric Neuro-Oncology Consortium

Terminated

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System Tumor

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Rainier Therapeutics

Terminated

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)

Urinary Bladder Disease | Locally Advanced or Metastatic Urothelial Cell Carcinoma | Urological Diseases

Italy, Spain, United States, Korea, Republic of, Turkey, Taiwan, Sweden, Czechia, United Kingdom
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Taiwan, Japan, China, Canada, Korea, Republic of, Israel, Argentina, Australia, Brazil, Mexico, United Kingdom
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Malignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE)

Glioma | Melanoma | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Neoplasms by Site | Cancer | Brain Neoplasms | Solid Tumor | Malignant Neoplasm | Malignancy | Haematological Malignancy

United Kingdom
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Brain Stem Neoplasm | Pineal Region Neoplasm | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma

United States
Piramal Enterprises Limited
Melanoma Research Foundation Breakthrough Consortium

Suspended

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Recurrent and Refractory Solid Tumors

United States, Canada
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell Carcinoma

United States
NantCell, Inc.
Takeda

Terminated

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)

Cancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine Cancer

Italy, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada
DualityBio Inc.

Recruiting

A Study of DB-1303 in Advanced/Metastatic Solid Tumors

HER2-positive Advanced Solid Tumor

China, United States, Australia, Puerto Rico
Hoffmann-La Roche

Active, not recruiting

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)

Solid Tumors | CNS Tumors

United States, Spain, Korea, Republic of, Canada, Germany, United Kingdom, China, Italy, Hong Kong, France, Taiwan
Amgen

Completed

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

United Kingdom, Czech Republic
AeRang Kim

Active, not recruiting

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Desmoid Tumor | Germ Cell Tumor | Relapsed Pediatric Solid Tumors | Refractory Pediatric Solid Tumors | Hepatic Tumor

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics

Recruiting

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Locally Advanced or Metastatic Urothelial Carcinoma

Korea, Republic of, United States, Taiwan, Australia, United Kingdom, France, Greece, Italy, Belgium, Spain, Canada, Denmark, Germany
Children's Oncology Group
National Cancer Institute (NCI); Incuron LLC

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Forma Therapeutics, Inc.

Completed

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) | Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Cohort 3a and 3b: Chondrosarcoma | Cohort 4a and 4b: Intrahepatic... and other conditions

United States, Korea, Republic of, Australia, United Kingdom, Spain, France
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland

Clinical Trials on Advanced or Refractory Solid Malignancies in Korea, Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations